Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-100 vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pure opioid agonist that binds to mu-opioid receptors in the CNS, mimicking endogenous endorphins to inhibit pain transmission. Also interacts with kappa and delta receptors. Therapeutic effects include analgesia, sedation, and euphoria.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment in opioid-tolerant patients,Off-label: Chronic pain in non-opioid-tolerant patients (not recommended due to risk of respiratory depression)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Transdermal patch; initial dose based on prior opioid use: for opioid-naive patients, 12 mcg/h every 72 hours; for opioid-tolerant patients, convert using equianalgesic tables; maximum dose 100 mcg/h per patch; apply to non-irritated, non-irradiated skin on chest, back, flank, or upper arm.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life approximately 20–27 hours after transdermal system removal (range 13–25 hours in healthy adults; prolonged in elderly, hepatic impairment, and cachexia).
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily metabolized by CYP3A4 isoenzyme to norfentanyl and other inactive metabolites. Minor pathways via CYP3A5. First-pass metabolism is extensive after oral administration, but transdermal delivery bypasses this.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal (primarily as metabolites, <10% unchanged fentanyl); fecal (about 9% of dose).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 80–85% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin; increased free fraction in hypoalbuminemia.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
3–8 L/kg (mean ~6 L/kg), indicating extensive tissue distribution (including deep compartments such as muscle and fat).
4-6 L/kg; large Vd indicates extensive tissue distribution
Transdermal: approximately 92% of the dose over 72 hours (systemic absorption fraction).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-60 m L/min: no adjustment required; GFR <30 m L/min: reduce dose by 50% and titrate cautiously; hemodialysis: not removed, avoid use or use with extreme caution.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce initial dose by 50% and titrate slowly; Child-Pugh class C: avoid use or reduce dose by 75% with careful monitoring.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For children ≥2 years old: initial dose 25 mcg/h for opioid-tolerant patients; for opioid-naive, use alternative analgesic; titrate in 12-25 mcg/h increments every 72 hours; do not use in children <2 years.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lowest available strength (12 mcg/h) and titrate slowly; monitor for respiratory depression, constipation, and cognitive effects; consider increased sensitivity to opioid effects.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of respiratory depression, especially in non-opioid-tolerant patients; risk of accidental exposure leading to fatal overdose; contraindicated in acute or postoperative pain; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of interaction with CYP3A4 inhibitors leading to fatal respiratory depression; risk of death from concomitant use with benzodiazepines or CNS depressants.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Life-threatening respiratory depression: monitor closely, especially during initiation and dose escalation,Accidental exposure: can cause fatal overdose in children; apply patch to dry, non-irritated skin on flat surface of upper torso,Neonatal opioid withdrawal syndrome: prolonged use during pregnancy can result in withdrawal in newborns,Risks from concomitant use with benzodiazepines or CNS depressants: additive sedation and respiratory depression,Risk of hypotension, bradycardia, and seizure in patients with compromised cardiovascular or cerebrovascular function,Serotonin syndrome when co-administered with serotonergic drugs,Adrenal insufficiency and androgen deficiency with long-term use,Severe hypotension in patients with reduced blood volume or concurrent drug therapy that compromises vasomotor tone,Biliary tract spasm and increased intracholedochal pressure,Avoid in patients with head injury, increased intracranial pressure, or impaired consciousness,Do not cut, chew, or swallow patch; apply patch immediately after removal from package; wear time 72 hours,Fever or external heat can increase absorption; avoid exposing application site to direct heat sources
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to fentanyl or any component of the patch,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI,Non-opioid-tolerant patients: contraindicated for acute pain, postoperative pain, mild/intermittent pain, or pain that can be managed by non-opioid analgesics,Pregnancy: prolonged use can cause neonatal opioid withdrawal syndrome,Lactation: fentanyl is excreted in breast milk; use caution
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit and grapefruit juice during therapy, as they can affect liver enzymes and alter fentanyl metabolism. No other specific food restrictions. However, a high-fat meal may delay absorption of oral fentanyl but this is not relevant for transdermal formulation. Maintain caution with alcohol intake as it can potentiate CNS depression.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Data insufficient to establish specific risk; fentanyl crosses placenta. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS). Use not recommended unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fentanyl excreted in breast milk; M/P ratio approximately 0.5. Limited data suggest low levels, but monitoring for infant sedation and respiratory depression recommended. Avoid use or use with caution.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Increased clearance during pregnancy may require dose adjustment; no specific guidelines. Close monitoring for efficacy and withdrawal; taper to avoid NOWS.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Duragesic-100 is a transdermal fentanyl patch delivering 100 mcg/h. Use only in opioid-tolerant patients due to risk of respiratory depression. Do not cut or damage the patch; apply to non-irritated, non-hairy skin on upper torso. Avoid heat sources (heating pads, saunas) as increased temperature can accelerate drug absorption, leading to fatal overdose. Monitor for signs of serotonin syndrome when co-administered with serotonergic drugs. Rotate application sites to minimize skin irritation.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Apply the patch to clean, dry, hairless skin on the chest, back, or upper arm. Do not shave the area; clip hair if necessary.,Do not cut, tear, or damage the patch. Use only as directed by your healthcare provider.,Avoid exposing the patch to direct heat sources such as heating pads, electric blankets, hot tubs, or prolonged sunbathing, as this can increase the amount of medicine absorbed and cause a fatal overdose.,Keep the patch away from children and pets, as exposure can be fatal. Dispose of used patches by folding them in half and flushing down the toilet or placing in a sealed container.,Do not stop using this medication suddenly without consulting your doctor, as withdrawal symptoms may occur.,Seek emergency help if you experience slow/shallow breathing, difficulty waking up, or extreme drowsiness.,Do not drink alcohol while using this medication, as it may increase the risk of serious side effects.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-100 vs ABSTRAL, answered by our medical review team.
DURAGESIC-100 is a Opioid Analgesic that works by Pure opioid agonist that binds to mu-opioid receptors in the CNS, mimicking endogenous endorphins to inhibit pain transmission. Also interacts with kappa and delta receptors. Therapeutic effects include analgesia, sedation, and euphoria.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-100 and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-100 is: Transdermal patch; initial dose based on prior opioid use: for opioid-naive patients, 12 mcg/h every 72 hours; for opioid-tolerant patients, convert using equianalgesic tables; maximum dose 100 mcg/h per patch; apply to non-irritated, non-irradiated skin on chest, back, flank, or upper arm.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-100 and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-100 is classified as Category C. First trimester: Data insufficient to establish specific risk; fentanyl crosses placenta. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS). . ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.